A landmark study led by the Wellcome Sanger Institute and University of Cambridge has systematically characterized DNA damage patterns caused by various chemotherapy drugs in healthy blood cells. This work identifies distinct mutational signatures linked to chemotherapy classes such as platinum agents and alkylating drugs, revealing differential impacts on somatic mutation rates. These insights have broad implications for optimizing cancer treatments to minimize long-term risks to healthy tissues.